Primatene Mist gets OTC reintroduction
Amphastar Pharmaceuticals is bringing its Primatene Mist back to OTC aisles. The Food and Drug Administration approved the product on Wednesday, making it the only agency-cleared nonprescription asthma inhaler in the United States. It is indicated to temporarily relieve mild symptoms of asthma in patients 12 years old and older.
The metered-dose inhaler had previously been taken off the market because it contained chlorofluorocarbon propellants. The new CFC-free version uses hydrofluoroalkane propellants and uses the same active ingredient, epinephrine, as the original Primatene Mist. It also features a built-in spray indicator and a metal canister that replaces the glass container used in the original Primatene Mist.
“We are very happy to have received FDA approval for Primatene Mist and are proud to bring this important product back to the over-the-counter market in the United States,” said Amphaster CEO Jack Zhang. “We are grateful to the FDA team for working closely with us to make this approval possible, recognizing the important role of OTC bronchodilator drugs such as Primatene Mist.”
FDA director Scott Gottlieb and Center for Drug Evaluation and Research director Janet Woodcock issued a joint statement Thursday, noting that the product comes with updated instructions, is not meant to replace a patient’s current treatment, nor meant to treat anything other than mild asthma, and should be used in consultation with a physician.
“The product is appropriate for mild symptoms of intermittent asthma, however, even patients with mild asthma can have severe exacerbations — so it’s still important to consult a healthcare provider about appropriate care and have their condition reassessed,” Gottlieb and Woodcock said. “And, of course, all patients who experience severe exacerbations should go to the emergency room right away.”
Amphastar said that Primatene Mist would be available in major drug stores in the United States starting in early 2019.
Durex goes (RED) with latest launch
RB’s Durex condom brand is partnering with non-profit (RED) to launch a special edition (Durex)RED condom, as well as a $5 million donation to the organization, which works to raise money through brand partnerships to fight HIV and AIDS in Africa.
The limited-edition condom is being offered online through Amazon, as well as in select retailers, including Target. Available in 12- and 42-count packs, the product will see 35 cents per purchase of the former and 84 cents per purchase of the latter go to a program in South Africa. The program, Keeping Girls in School, works to reduce HIV infections and pregnancy among young women through educational programs and access to sexual health and reproductive services.
“This meaningful partnership between Durex and (RED) stands for the responsibility we all have, as individuals and organizations, to join the fight against HIV and AIDS around the world,” said Nadja Körner, marketing Director for sexual wellbeing at RB. “We want our consumers to feel empowered to take action and quite literally ‘Have Sex and Save Lives’ through the purchase of the new (Durex)RED condom.
As part of the launch, the company has released a provocative short film encouraging users to show their support using the hashtag #HaveSexSaveLives. The film includes singer Zara Larsson, actor Thandie Newton, Broadway star Javier Muñoz, influencer Tyler Oakley, rapper/singer Jacob Latimore and actor Christian Navarro.
“It is exhilarating for (RED) to partner with a global brand like Durex in such a provocative, inspiring and creative way. In addition to millions of dollars to the Global Fund, there is brilliance and beauty in a (RED) partner product that saves lives in more ways than one,” said Deborah Dugan, CEO of (RED). “Thank you to all at Durex for bringing this important campaign to people and places all around the world.”
Deloitte: Wearables drive consumer health engagement
The number of U.S. consumers tracking their health data with wearables has more than doubled since 2013, and they also are becoming more engaged in their own health care through use of technology and data sharing solutions, according to new research from the Deloitte Center for Health Solutions.
The Deloitte 2018 Survey of U.S. Health Care Consumers surveyed 4,530 U.S. adults and found that roughly one-third of consumers said they are interested in using digital tools, apps and at-home diagnostic tests for identifying symptoms and for health coaching.
About half, 51% of respondents, were comfortable using an at-home test to diagnose infections before seeing a doctor. More than 35% of respondents said they are interested in using a virtual assistant to identify symptoms and direct them to a caregiver.
A similar amount (31%) are interested in connecting with a live health coach who offers 24/7 text messaging for nutrition, exercise, sleep and stress management.
The study also found that 60% of consumers said they are willing to share personal health data from devices with their doctor to improve their health.
Of those who used wearables in the past year, 73% said they used them consistently, which the report said runs counter to past studies that showed that fitness devices had a high rate of abandonment.